SGLT2i, Ketoacidosis, Volume Contraction, and Insulinopenia

Part of paid clinical trials in San Antonio, Texas.

Sponsor
The University of Texas Health Science Center at San Antonio
Study ID
NCT07053306
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
30 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Empagliflozin 25 MG — DRUG
    A medication used in the management and treatment of type 2 diabetes mellitus. It is in the sodium-glucose co-transporter (SGLT-2) class of medications.

Study Details

To examine the 2-HIT hypothesis that the SGLT2i-induced stimulation of EGP, lipolysis, and ketone production requires the combination of volume depletion plus insulinopenia in T2D individuals.

Key Dates

Start date
Apr 29, 2025
Status verified
Jul 2025
Primary completion
Jun 1, 2027
Completion
Jun 30, 2027

Study Design

Enrollment
29 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Empagliflozin
    Empagliflozin 25 mg/day

Primary Outcome Measure

Ketone Body Turnover (ketogenesis) [ Time Frame: 0 and 300 minutes ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Texas Diabetes Institute/UHSan AntonioTexas78229-3900
Ralph DeFronzo, MD
[email protected]
210-358-7200
Aurora Merovci, MD
[email protected]
210-567-6691
Ralph DeFronzo, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in San Antonio, TX

By condition
Type 2 diabetes
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
Texas Diabetes Institute/UH· San Antonio, TX

Related Studies